SRDX Surmodics Inc
Price (delayed)
$28.55
Market cap
$408.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
$407.6M
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics
Highlights
SRDX's quick ratio is up by 25% since the previous quarter and by 11% year-on-year
The net income has declined by 25% since the previous quarter
The company's EPS fell by 24% QoQ
Key stats
What are the main financial stats of SRDX
Market
Valuations
Earnings
Shares outstanding
14.3M
Market cap
$408.15M
Enterprise value
$407.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.66
Price to sales (P/S)
3.24
EV/EBIT
N/A
EV/EBITDA
132.64
EV/Sales
3.25
Revenue
$125.45M
Gross profit
$93.8M
Operating income
-$7.8M
Net income
-$14.41M
EBIT
-$6.2M
EBITDA
$3.07M
Free cash flow
-$1.93M
Per share
Balance sheet
Liquidity
EPS
-$1.02
EPS diluted
-$1.02
Free cash flow per share
-$0.14
Book value per share
$7.8
Revenue per share
$8.82
TBVPS
$7.03
Total assets
$163.74M
Total liabilities
$51.97M
Debt
$29.59M
Equity
$111.77M
Working capital
$58.66M
Debt to equity
0.26
Current ratio
5.45
Quick ratio
3.24
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
2.4%
Gross margin
74.8%
Net margin
-11.5%
Operating margin
-6.2%
Return on assets
-8.2%
Return on equity
-12.2%
Return on invested capital
-7%
Return on capital employed
-4.1%
Return on sales
-4.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SRDX stock price
How has the Surmodics stock price performed over time
Intraday
3.55%
1 week
0.39%
1 month
-6.02%
1 year
7.78%
YTD
-27.9%
QTD
-6.49%
Financial performance
How have Surmodics's revenue and profit performed over time
Revenue
$125.45M
Gross profit
$93.8M
Operating income
-$7.8M
Net income
-$14.41M
Gross margin
74.8%
Net margin
-11.5%
SRDX's operating margin has dropped by 171% year-on-year and by 38% since the previous quarter
The operating income has plunged by 165% YoY and by 38% from the previous quarter
The net income has declined by 25% since the previous quarter
The net margin has declined by 25% since the previous quarter
Growth
What is Surmodics's growth rate over time
Valuation
What is Surmodics stock price valuation
P/E
N/A
P/B
3.66
P/S
3.24
EV/EBIT
N/A
EV/EBITDA
132.64
EV/Sales
3.25
The company's EPS fell by 24% QoQ
The stock's price to book (P/B) is 22% less than its 5-year quarterly average of 4.5 and 22% less than its last 4 quarters average of 4.5
Surmodics's equity has decreased by 8% YoY and by 6% QoQ
SRDX's P/S is 39% below its 5-year quarterly average of 5.1 and 25% below its last 4 quarters average of 4.2
SRDX's revenue is down by 9% YoY
Efficiency
How efficient is Surmodics business performance
The company's return on sales has shrunk by 151% YoY and by 58% QoQ
The ROIC has plunged by 144% YoY and by 63% from the previous quarter
SRDX's return on assets is down by 28% since the previous quarter
The ROE has contracted by 27% from the previous quarter
Dividends
What is SRDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SRDX.
Financial health
How did Surmodics financials performed over time
The current ratio has grown by 38% from the previous quarter and by 13% YoY
SRDX's quick ratio is up by 25% since the previous quarter and by 11% year-on-year
The debt is 74% smaller than the equity
The debt to equity has grown by 8% YoY and by 4% from the previous quarter
Surmodics's equity has decreased by 8% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.